Coverage
Filings
| Filing | Date |
|---|---|
| Linerixibat GLISTEN pIII trial data at EASL | 8 May 2025 |
| Director/PDMR Shareholding | 8 May 2025 |
| Director/PDMR Shareholding | 8 May 2025 |
| Transaction in Own Shares | 7 May 2025 |
| Result of AGM | 7 May 2025 |
| Transaction in Own Shares | 6 May 2025 |
| Transaction in Own Shares | 2 May 2025 |
| Transaction in Own Shares | 1 May 2025 |
| Nucala MATINEE data in COPD published in NEJM |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 1 May 2025 |
| Total Voting Rights | 1 May 2025 |
| Director/PDMR Shareholding | 1 May 2025 |
| 1st Quarter Results | 30 Apr 2025 |